ECM
ESPR

Element Capital Management’s Esperion Therapeutics ESPR Stock Holding History

Element Capital Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-6,047
Closed -$243K – 404
2019
Q1 		$243K Buy
+6,047
New +$271K 0.01% 679

Other funds holding ESPR

BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Element Capital Management's ESPR Position: Q2 2019 in Review

Element Capital Management sold out of Esperion Therapeutics (ESPR) in Q2 2019, closing a stake of 6,047 shares — an estimated $243K sold.

Element Capital Management first reported a position in ESPR in Q1 2019 and held it in 1 quarter. The position peaked at $243K in Q1 2019. 167 funds tracked by Wall St. Rank hold ESPR as of Q2 2019.

  • Element Capital Management reported no remaining Esperion Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Element Capital Management sold 6,047 Esperion Therapeutics shares in Q2 2019, an estimated $243K.
  • Element Capital Management first reported a position in Esperion Therapeutics in Q1 2019 and held it in 1 quarter.
  • Element Capital Management's Esperion Therapeutics position peaked at $243K in Q1 2019.
  • 167 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2019.

Based on Element Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.